# This Page Is Inserted by IFW Operations and is not a part of the Official Record

### **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Application No. 10/079,137
Reply to Restriction Requirement dated March 15, 2004

APR 1 5 2004

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### **Listing of Claims:**

- 1. (Currently Amended) An isolated polynucleotide comprising a sequence selected from the group consisting of:
  - (a) the sequences provided in SEQ ID NO:341-344343;
  - (b) the complements of the sequences provided in SEQ ID NO:341-344343;
- (c) sequences consisting of at least 20 contiguous residues of a-the sequence provided in SEQ ID NO:341-344343;
- (d) sequences that hybridize to a-the sequence provided in SEQ ID NO:341-344343, under highly stringent conditions;
- (e) sequences having at least 75% identity to a-the sequence of SEQ ID NO:341-344343;
- (f) sequences having at least 90% identity to a—the sequence of SEQ ID NO:341-344343; and
  - (g) degenerate variants of a <u>the</u> sequence provided in SEQ ID NO:<del>341</del>-344343.
  - 2. (Canceled)
- 3. (Original) An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
- 4. (Original) A host cell transformed or transfected with an expression vector according to claim 3.
  - 5.-7. (Canceled)
- 8. (Currently Amended) An oligonucleotide that hybridizes to a the sequence recited in SEQ ID NO:341-344343 under highly stringent conditions.
  - 9.-10. (Canceled)
- 11. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of: comprising the polynucleotide according to claim 1.
  - (a) polypeptides according to claim 2;
  - (b) polynucleotides according to claim 1;

Application No. 10/079,137 Reply to Restriction Requirement dated March 15, 2004

- (c) antibodies according to claim 5;
- (d) fusion proteins according to claim 7;
- (e) T cell populations according to claim 10; and
- (f) antigen presenting cells that express a polypeptide according to claim 2.

12.-14. (Canceled)

15. (Original) A diagnostic kit comprising at least one oligonucleotide according to claim 8.

16.-17. (Canceled)